CoChat

ADHD - New Directions in Diagnosis and Treatment

Open access
Jill M. Norvilitis · 2015 · InTech eBooks

The DOI matches its Crossref record; 60 of the 81 references it cites were found in a registry or an index, and 19 are not checked yet.

Abstract

With many children and adults affected by Attention Deficit Hyperactivity Disorder, researchers strive to improve our understanding of the causes, consequences, and treatment of the disorder. This volume examines some of the broad arrays of research in the field of ADHD, from etiology to cutting-edge interventions. The 16 chapters explore topics ranging from comorbidity to advances in the search for biomarkers; to executive, cognitive, and social functioning; to the use of new and alternative therapies. Both the professional and the casual reader alike will find something of interest, whether learning about ADHD for the first time or looking for inspiration for new research questions or potential interventions.

Overview

Integrity signals

Registry

Crossref · 10.5772/59348

Cites

0 citation errors · 2 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Research works printed but not linked: 952

  1. American Academy of Pediatrics Clinical. Practice guideline: diagnosis and evalua- tion of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000; 105: 1158-1170.
  2. Merrell C, Tymms PB. Inattention, hyperactivity and impulsiveness: their impact on academic achievement and progress. British Journal of Educational Psychology 2001; 71: 43-56.
  3. Bakare MO. Attention deficit hyperactivity symptoms and disorder (ADHD) among African children: a review of epidemiology and co-morbidities. African Journal of Psychiatry 2002; 15: 358-361
  4. Ambuabunos EA, Ofovwe EG, Ibadin MO. Community survey of attention-deficit/ hyperactivity disorder among primary school pupils in Benin City, Nigeria. Annals of African Medicine 2011; 1: 91-96
  5. Alqahtani MM. Attention-deficit hyperactive disorder in school-aged children in Saudi Arabia. European Journal of Pediatrics 2010; 169: 1113-1117
  6. Talaei A, Mokhber N, Abdollahian E, Bordbar MR, Salari E. Attention deficit/hyper- activity disorder: a survey on prevalence rate among male subjects in elementary school (7-9 years old) in Iran. Journal of Attention Disorders 2010; 13: 386-390.
  7. Rohde LA, Biederman J, Busnello EA, Zimmermann H, Schmitz M, Martins S, Tra- montina S. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments. Journal of the American Academy of Child and Adolescent Psychiatry 1999; 38: 716-722.
  8. Gadow KD, Nolan EE, Litcher L, Carlson GA, Panina N, Golovakha E, Sprafkin J, Bromet EJ. Comparison of attention-deficit/hyperactivity disorder symptom sub- types in Ukrainian schoolchildren. Journal of the American Academy of Child and Adolescent Psychiatry 2000; 39: 1520-1527.
  9. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012; 9: 490-499.
  10. Gaub M, Carlson C. Gender differences in ADHD: a meta-analysis and critical re- view. Journal of the American Academy of Child and Adolescent Psychiatry 1997; 36: 1036-1045, 1436-1441.
  11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disor- ders, Fifth Edition: DSM-5. Washington: American Psychiatric Association, 2013.
  12. Emond V, Joyal C, Poissant H. Structural and functional neuroanatomy of attention- deficit hyperactivity disorder (ADHD). Encephale. 2009; 35: 107-114
  13. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivi- ty disorder: current perspectives. Journal of the American Academy of Child and Adolescent Psychiatry. 1996; 35: 264-272.
  14. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology, Eighth Edition. New York, NY: Oxford University Press; 2003.
  15. Mary G, Michael S, Meaghan M, Wendy S, Deanna G, Francois L, et al. Developmen- tal trajectories of the corpus callosum in attention-deficit/hyperactivity disorder. Bio- logical Psychiatry 2011; 69: 839-846.
  16. Deeann W, Heather F, Maximilian M. Review: genetics of attention deficit/hyperac- tivity disorder. Journal of Pediatric Psychology 2008; 33: 1085-1099.
  17. Carsten O, Jørn O, Tine BH, Alina R, Marjo-Riitta J, Irma M, et al. Is maternal smok- ing during pregnancy a risk factor for hyperkinetic disorder?-findings from a sib- ling design. International Journal of Epidemiology 2011; 40: 338-345.
  18. Linnet KM, Dalsgaard S, Obel C, Wisborg K, Henriksen TB, Rodriguez A, et al. Ma- ternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. American Journal of Psy- chiatry 2003; 160: 1028-1040.
  19. Bekdas M, Tufan AE, Hakyemez IN, Tas T, Altunhan H, Demircioglu F, et al. Sub- clinical immune reactions to viral infections may correlate with child and adolescent diagnosis of attention-deficit/hyperactivity disorder: a preliminary study from Tur- key. African Health Sciences 2014; 14: 439-445.
  20. Cox ER, Halloran DR, Homan S, Welliver S, Mager DE. Trends in the prevalence of chronic medication use in children: 2002-2005. Pediatrics 2008; 122: 1053-1061. http:// www.biomedcentral.com/sfx_links?ui=1471-2431-12-78&bibl=B22#.75;.75
  21. Schirm E, Tobi H, Zito J, de Jong-van den Berg L. Psychotropic medication in chil- dren: a study from the Netherlands. Pediatrics 2001, 108: 25.
  22. Zuvekas S, Vitiello B, Norquist G. Recent trends in stimulant medication use among U.S. children. American Journal of Psychiatry 2006; 163: 579-585.
  23. Hodgkins P, Sasane R, Meijer WM. Pharmacologic treatment of attention deficit/ hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clinical Therapeutics 2011; 33: 188-203. http://www.biomedcen- tral.com/sfx_links?ui=1471-2431-12-78&bibl=B24#.75;.75
  24. Rushton J, Whitmire T. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. Archives of Pediatrics and Adolescent Medicine 2001; 155: 560-565.
  25. Barkley RA. Attention-Deficit Hyperactivity Disorder a Handbook for Diagnosis and Treatment, 3rd edition. New York Guilford Press, 2006.
  26. Walitza S, Drechsler R, Ball J. The school child with ADHD. Therapeutische Um- schau 2012; 69: 467-473.
  27. McBurnett K, Pfiffner LJ. Treatment of aggressive ADHD in children and adoles- cents: conceptualization and treatment of comorbid behavior disorders. Postgraduate Medicine 2009; 121: 158-165.
  28. Anderson JC, Williams S, McGee R, et al. DSM-III disorders in preadolescent chil- dren: prevalence in a large community sample. Archives of General Psychiatry. 1998; 44: 69-76.
  29. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity dis- order with conduct, depressive, anxiety, and other disorders. American Journal of Psychiatry 1991; 148: 564-577.
  30. Bitsko RH, Holbrook JR, Visser SN, Mink JW, Zinner SH, Ghandour RM, et al. A na- tional profile of Tourette syndrome, 2011-2012. Journal of Developmental and Be- havioral Pediatrics 2008; 35: 317-322.
  31. Bitsko RH, Holbrook JR, Visser SN, Mink JW, Zinner, Samuel H, et al. A National Profile of Tourette Syndrome, 2011-2012. Journal of Developmental and Behavioral Pediatrics 2014; 35; 317-322.
  32. Florence L, David AH, Kellie SB, Michael M. Gender differences in ADHD subtype comorbidity. Journal of the American Academy of Child and Adolescent Psychiatry 2005; 44; 368-376.
  33. Altarac M, Saroha E. Lifetime prevalence of learning disability among US children. Pediatrics 2007; 119: S77-S83.
  34. Szatmari P, Offord DR, Boyle MH. Correlates, associated impairments and patterns of service utilization of children with attention deficit disorder: findings from the On- tario Child Health Study. Journal of Child Psychology and Psychiatry 1989; 30: 205- 217.
  35. Messer J, Maughan B, Quinton D, Taylor A. Precursors and correlates of criminal be- haviour in women. Criminal Behaviour and Mental Health 2004; 14: 82-107.
  36. Gunter TD, Arndt S, Riggins-Caspers K, Wenman G, Cadoret RJ. Adult outcomes of attention deficit hyperactivity disorder and conduct disorder: are the risks independ- ent or additive? Annals of Clinical Psychiatry 2006; 18: 233-237.
  37. Satterfield JH, Schell A. A prospective study of hyperactive boys with conduct prob- lems and normal boys: adolescent and adult criminality. Journal of the American Academy of Child and Adolescent Psychiatry 1997; 36: 1726-1735. Epidemiology of Attention Deficit/Hyperactivity Disorder http://dx.doi.org/10.5772/61016 · DOI
  38. Ronald A, Larsson H, Anckarsäter H, Lichtenstein P. A twin study of autism symp- toms in Sweden. Molecular Psychiatry 2011; 16: 1039-1047.
  39. Lichtenstein P, Carlström E, Råstam M, Gillberg C, Anckarsäter H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. American Journal of Psychiatry 2010; 167: 1357-1363.
  40. Victoria L, Josephine E, Christopher E, Stuart B, Nathan B, Karen U, et al. Cardiovas- cular monitoring of children and adolescents with heart disease receiving medica- tions for attention deficit/hyperactivity disorder. Circulation 2008; 117: 2407-2423.
  41. Mellon MW, Natchev BE, Katusic SK, Colligan RC, Weaver AL, Voigt RG, et al. Inci- dence of enuresis and encopresis among children with attention-deficit/hyperactivity disorder in a population-based birth cohort. Academic Pediatrics 2013; 13: 322-327.
  42. Johnston BD, Wright JA. Attention dysfunction in children with encopresis. Journal of Developmental and Behavioral Pediatrics 1993; 14: 381-385. References
  43. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Mo- lecular genetics of attention-deficit/hyperactivity disorder. Biological Psychiatry 2005; 57: 1313-23.
  44. Rohde LA, Halpern R. Recent advances on attention deficit/hyperactivity disorder. Jornal de Pediatria 2004; 80: 61-70.
  45. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge University Press; 2013.
  46. Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, et al. Pat- terns and predictors of attention-deficit/hyperactivity disorder persistence into adult- hood: results from the national comorbidity survey replication. Biological Psychiatry 2005; 57: 1442-51.
  47. Amor LB, Grizenko N, Schwartz G, Lageix P, Baron C, Ter-Stepanian M, et al. Perina- tal complications in children with attention-deficit hyperactivity disorder and their unaffected siblings. Journal of Psychiatry and Neuroscience 2005; 30: 120.
  48. Biederman J, Milberger S, Faraone SV, Kiely K, Guite J, Mick E, et al. Impact of ad- versity on functioning and comorbidity in children with attention-deficit hyperactivi- ty disorder. Journal of the American Academy of Child & Adolescent Psychiatry 1995; 34: 1495-503.
  49. Biederman J, Milberger S, Faraone SV, Kiely K, Guite J, Mick E, et al. Family-environ- ment risk factors for attention-deficit hyperactivity disorder: a test of Rutter's indica- tors of adversity. Archives of General Psychiatry 1995; 52: 464-70.
  50. McIntosh DE, Mulkins RS, Dean RS. Utilization of maternal perinatal risk indicators in the differential diagnosis of ADHD and UADD children. International Journal of Neuroscience 1995; 81: 35-46.
  51. Sprich-Buckminster S, Biederman J, Milberger S, Faraone SV, Lehman BK. Are peri- natal complications relevant to the manifestation of ADD? Issues of comorbidity and familiality. Journal of the American Academy of Child & Adolescent Psychiatry 1993; 32: 1032-7.
  52. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-defi- cit hyperactivity disorder. Acta Paediatrica 2007; 96: 1269-74.
  53. Senol S, Sener S, Ergenekon E, Gücüyener K. The impact of pre-and perinatal factors on attention-deficit and disruptive behavior disorders. The Turkish ournal of Pedia- trics 2000; 43: 231-6.
  54. Hultman CM, Torrång A, Tuvblad C, Cnattingius S, Larsson J-O, Lichtenstein P. Birth weight and attention-deficit/hyperactivity symptoms in childhood and early adolescence: a prospective Swedish twin study. Journal of the American Academy of Child & Adolescent Psychiatry 2007; 46: 370-7.
  55. Sasaluxnanon C, Kaewpornsawan T. Risk factor of birth weight below 2,500 grams and attention deficit hyperactivity disorder in Thai children. Journal-Medıcal Assocı- atıon of Thaıland 2005; 88: 1514.
  56. Levy F, Barr C, Sunohara G. Directions of aetiologic research on attention deficit hy- peractivity disorder. Australian and New Zealand Journal of Psychiatry 1998; 32: 97-103.
  57. Pettersson E, Sjölander A, Almqvist C, Anckarsäter H, D'Onofrio BM, Lichtenstein P, et al. Birth weight as an independent predictor of ADHD symptoms: a within-twin pair analysis. Journal of Child Psychology and Psychiatry 2014; 56:453-9.
  58. Indredavik M, Vik T, Heyerdahl S, Kulseng S, Fayers P, Brubakk A. Psychiatric symptoms and disorders in adolescents with low birth weight. Archives of Disease in Childhood-Fetal and Neonatal Edition 2004; 89: F445-50.
  59. Thapar A, Rutter M. Do prenatal risk factors cause psychiatric disorder? Be wary of causal claims. The British Journal of Psychiatry 2009; 195: 100-1.
  60. Elgen I, Sommerfelt K, Markestad T. Population based, controlled study of behaviou- ral problems and psychiatric disorders in low birthweight children at 11 years of age. Archives of Disease in Childhood-Fetal and Neonatal Edition 2002; 87: F128-32.
  61. D'Onofrio BM, Lahey BB, Turkheimer E, Lichtenstein P. Critical need for family- based, quasi-experimental designs in integrating genetic and social science research. American Journal of Public Health 2013; 103: S46-55.
  62. Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand K. Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. JAMA 2002; 288: 728-37.
  63. Ficks CA, Lahey BB, Waldman ID. Does low birth weight share common genetic or environmental risk with childhood disruptive disorders? Journal of Abnormal Psy- chology 2013; 122: 842.
  64. Galéra C, Côté SM, Bouvard MP, Pingault J-B, Melchior M, Michel G, et al. Early risk factors for hyperactivity-impulsivity and inattention trajectories from age 17 months to 8 years. Archives of General Psychiatry 2011; 68: 1267-75.
  65. Chang Z, Lichtenstein P, D'Onofrio BM, Almqvist C, Kuja-Halkola R, Sjölander A, et al. Maternal age at childbirth and risk for ADHD in offspring: a population-based co- hort study. International Journal of Epidemiology 2014: dyu204.
  66. Talge NM, Neal C, Glover V. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? Journal of Child Psychology and Psychiatry 2007; 48(3-4): 245-61.
  67. Weinstock M. Alterations induced by gestational stress in brain morphology and be- haviour of the offspring. Progress in Neurobiology 2001; 65: 427-51.
  68. Glover V. Prenatal stress and its effects on the fetus and the child: possible underly- ing biological mechanisms. In: Perinatal Programming of Neurodevelopment. Springer; 2015, p. 269-83.
  69. Teixeira J, Fisk NM, Glover V. Association between maternal anxiety in pregnancy and increased uterine artery resistance index: cohort based study. BMJ 1999; 318: 153-7.
  70. Pauly JR, Slotkin TA. Maternal tobacco smoking, nicotine replacement and neurobe- havioural development. Acta Paediatrica 2008; 97: 1331-7.
  71. Alp H, Selimoğlu MA, Yaman S, Energin M, Altınkaynak S, Orbak Z. Gebelikte si- gara kullanımının fetüsa etkileri. İstanbul Çocuk Kliniği Dergisi 1995; 30: 80-3.
  72. Özsoy S. Gebelikte sigara içme alışkanlığı ve evde sigara içilmesinin doğum şekli ve bebeğin doğum tartısı üzerine etkisi. Hemşirelik Bülteni 1992; 6: 25; 26.
  73. Semiz O, Sözeri C, Cevahir R, Şahin S, Kılıçoğlu SS. Sakarya'da bir sağlık kuruluşuna başvuran gebelerin sigara içme durumlarıyla ilgili bazı özellikler. STED 2006; 15: 149-52.
  74. Marakoğlu K, Sezer RE. Sivas' ta gebelikte sigara kullanımı. Cumhuriyet Üniversitesi Tıp Fakültesi Dergisi 2003; 25: 157-64.
  75. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? The American Journal of Psychiatry 1996; 153(9):1138-1142.
  76. Suzuki K, Minei L, Johnson E. Effect of nicotine upon uterine blood flow in the preg- nant rhesus monkey. American Journal of Obstetrics Gynecology 1980; 136: 1009-13.
  77. Milberger S, Biederman J, Faraone SV, Jones J. Further evidence of an association be- tween maternal smoking during pregnancy and attention deficit hyperactivity disor- der: findings from a high-risk sample of siblings. Journal of Clinical Child Psychology 1998; 27: 352-8.
  78. Wasserman RC, Kelleher KJ, Bocian A, Baker A, Childs GE, Indacochea F, et al. Iden- tification of attentional and hyperactivity problems in primary care: a report from pe- diatric research in office settings and the ambulatory sentinel practice network. Pediatrics 1999; 103: e38-e.
  79. Ernst M, Moolchan ET, Robinson ML. Behavioral and neural consequences of prena- tal exposure to nicotine. Journal of the American Academy of Child & Adolescent Psychiatry 2001; 40: 630-41.
  80. Todd RD, Neuman RJ. Gene-environment interactions in the development of com- bined type ADHD: evidence for a synapse-based model. American Journal of Medi- cal Genetics Part B: Neuropsychiatric Genetics 2007; 144: 971-5.
  81. Hjern A, Weitoft GR, Lindblad F. Social adversity predicts ADHD-medication in school children-a national cohort study. Acta Paediatrica 2010; 99: 920-4.
  82. Han J-Y, Kwon H-J, Ha M, Paik K-C, Lim M-H, Lee SG, et al. The effects of prenatal exposure to alcohol and environmental tobacco smoke on risk for ADHD: a large population-based study. Psychiatry Research 2014; 225(1):164-168.
  83. Kotimaa AJ, Moilanen I, Taanila A, Ebeling H, Smalley SL, Mcgough JJ, et al. Mater- nal smoking and hyperactivity in 8-year-old children. Journal of the American Acad- emy of Child & Adolescent Psychiatry 2003; 42: 826-33.
  84. Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? Journal of Phar- macology and Experimental Therapeutics 1998; 285: 931-45.
  85. Seidler F, Levin E, Lappi S, Slotkin T. Fetal nicotine exposure ablates the ability of postnatal nicotine challenge to release norepinephrine from rat brain regions. Devel- opmental Brain Research 1992; 69: 288-91.
  86. Sheese BE, Voelker PM, Rothbart MK, Posner MI. Parenting quality interacts with ge- netic variation in dopamine receptor D4 to influence temperament in early child- hood. Development and Psychopathology 2007; 19: 1039-46.
  87. Neuman RJ, Lobos E, Reich W, Henderson CA, Sun L-W, Todd RD. Prenatal smok- ing exposure and dopaminergic genotypes interact to cause a severe ADHD subtype. Biological Psychiatry 2007; 61: 1320-8.
  88. Altink ME, Arias-Vásquez A, Franke B, Slaats-Willemse DI, Buschgens CJ, Rom- melse NN, et al. The dopamine receptor D4 7-repeat allele and prenatal smoking in ADHD-affected children and their unaffected siblings: no gene-environment interac- tion. Journal of Child Psychology and Psychiatry 2008; 49: 1053-60.
  89. Becker K, El-Faddagh M, Schmidt MH, Esser G, Laucht M. Interaction of dopamine transporter genotype with prenatal smoke exposure on ADHD symptoms. The Jour- nal of Pediatrics 2008; 152: 263-9. e1.
  90. Button TMM, Maughan B, McGuffin P. The relationship of maternal smoking to psy- chological problems in the offspring. Early Human Development 2007; 83: 727-32.
  91. Olney J, Ishimaru M, Bittigau P, Ikonomidou C. Ethanol-induced apoptotic neurode- generation in the developing brain. Apoptosis 2000; 5: 515-21.
  92. Sowell ER, Mattson S, Thompson P, Jernigan T, Riley E, Toga A. Mapping callosal morphology and cognitive correlates Effects of heavy prenatal alcohol exposure. Neurology 2001; 57: 235-44.
  93. Huizink AC, Mulder EJ. Maternal smoking, drinking or cannabis use during preg- nancy and neurobehavioral and cognitive functioning in human offspring. Neuro- science & Biobehavioral Reviews 2006; 30: 24-41.
  94. Streissguth AP, Barr HM, Sampson PD. Moderate prenatal alcohol exposure: effects on child IQ and learning problems at age 7 1/2 years. Alcoholism: Clinical and Exper- imental Research 1990; 14: 662-9.
  95. Knopik VS, Heath AC, Jacob T, Slutske WS, Bucholz KK, Madden PA, et al. Maternal alcohol use disorder and offspring ADHD: disentangling genetic and environmental effects using a children-of-twins design. Psychological Medicine 2006; 36: 1461-71.
  96. Leech S, Richardson GA, Goldschmidt L, Day N. Prenatal substance exposure: effects on attention and impulsivity of 6-year-olds. Neurotoxicology and Teratology 1999; 21: 109-18.
  97. Rodriguez A, Olsen J, Kotimaa A, Kaakinen M, Moilanen I, Henriksen TB, et al. Is prenatal alcohol exposure related to inattention and hyperactivity symptoms in chil- dren? Disentangling the effects of social adversity. Journal of Child Psychology and Psychiatry 2009; 50: 1073-83.
  98. D'Onofrio BM, Van Hulle CA, Waldman ID, Rodgers JL, Rathouz PJ, Lahey BB. Causal inferences regarding prenatal alcohol exposure and childhood externalizing problems. Archives of General Psychiatry 2007; 64: 1296-304.
  99. Yolton K, Cornelius M, Ornoy A, McGough J, Makris S, Schantz S. Exposure to neu- rotoxicants and the development of attention deficit hyperactivity disorder and its related behaviors in childhood. Neurotoxicology and Teratology 2014; 44: 30-45.
  100. Meyer JS, Shearman LP, Collins LM. Monoamine transporters and the neurobehavio- ral teratology of cocaine. Pharmacology Biochemistry and Behavior 1996; 55(4): 585-93.
  101. Richardson GA, Goldschmidt L, Willford J. Continued effects of prenatal cocaine use: preschool development. Neurotoxicology and Teratology 2009; 31: 325-33.
  102. Linares TJ, Singer LT, Kirchner HL, Short EJ, Min MO, Hussey P, et al. Mental health outcomes of cocaine-exposed children at 6 years of age. Journal of Pediatric Psychol- ogy 2006; 31: 85-97.
  103. Bada HS, Bann CM, Bauer CR, Shankaran S, Lester B, LaGasse L, et al. Preadolescent behavior problems after prenatal cocaine exposure: relationship between teacher and caretaker ratings (Maternal Lifestyle Study). Neurotoxicology and Teratology 2011; 33: 78-87.
  104. Richardson GA, Hamel SC, Goldschmidt L, Day NL. The effects of prenatal cocaine use on neonatal neurobehavioral status. Neurotoxicology and Teratology 1996; 18: 519-28.
  105. Richardson GA, Goldschmidt L, Willford J. The effects of prenatal cocaine use on in- fant development. Neurotoxicology and Teratology 2008; 30: 96-106.
  106. Richardson GA, Goldschmidt L, Leech S, Willford J. Prenatal cocaine exposure: ef- fects on mother-and teacher-rated behavior problems and growth in school-age chil- dren. Neurotoxicology and Teratology 2011; 33: 69-77.
  107. Richardson GA, Larkby C, Goldschmidt L, Day NL. Adolescent initiation of drug use: effects of prenatal cocaine exposure. Journal of the American Academy of Child & Adolescent Psychiatry 2013; 52: 37-46.
  108. Wilson GS, McCreary R, Kean J, Baxter JC. The development of preschool children of heroin-addicted mothers: a controlled study. Pediatrics 1979; 63: 135-41.
  109. De Cubas MM, Field T. Children of methadone-dependent women: developmental outcomes. American Journal of Orthopsychiatry 1993; 63(2):266-76.
  110. Slinning K. Foster placed children prenatally exposed to poly-substances. European Child & Adolescent Psychiatry 2004; 13: 19-27.
  111. Ornoy A, Ergaz Z. Alcohol abuse in pregnant women: effects on the fetus and new- born, mode of action and maternal treatment. International Journal of Environmental Research and Public Health 2010; 7: 364-79.
  112. Ornoy A. The impact of intrauterine exposure versus postnatal environment in neu- rodevelopmental toxicity: long-term neurobehavioral studies in children at risk for developmental disorders. Toxicology Letters 2003; 140: 171-81.
  113. Kanarek RB. Does sucrose or aspartame cause hyperactivity in children? Nutrition Reviews 1994; 52: 173-5.
  114. Needleman HL. Lead and impaired abilities. Developmental Medicine & Child Neu- rology 1982; 24: 196-7.
  115. Collipp P, Chen S, Maitinsky S. Manganese in infant formulas and learning disabili- ty. Annals of Nutrition and Metabolism 1983; 27: 488-94.
  116. Control CfD, Prevention. Blood lead levels--United States, 1999-2002. MMWR Mor- bidity and Mortality Weekly Report 2005; 54: 513.
  117. Eubig PA, Aguiar A, Schantz SL. Lead and PCBs as risk factors for attention deficit/ hyperactivity disorder. Environmental health perspectives 2010; 118: 1654-67.
  118. Chiodo LM, Jacobson SW, Jacobson JL. Neurodevelopmental effects of postnatal lead exposure at very low levels. Neurotoxicology and Teratology 2004; 26: 359-71.
  119. Morgan RE, Garavan H, Smith EG, Driscoll LL, Levitsky DA, Strupp BJ. Early lead exposure produces lasting changes in sustained attention, response initiation, and re- activity to errors. Neurotoxicology and Teratology 2001; 23: 519-31.
  120. Stewart PW, Lonky E, Reihman J, Pagano J, Gump BB, Darvill T. The relationship be- tween prenatal PCB exposure and intelligence (IQ) in 9-year-old children. Environ- mental Health Perspectives 2008; 116(10):1416-22.
  121. Jacobson JL, Jacobson SW. Prenatal exposure to polychlorinated biphenyls and atten- tion at school age. The Journal of Pediatrics 2003; 143: 780-8.
  122. Stewart P, Fitzgerald S, Reihman J, Gump B, Lonky E, Darvill T, et al. Prenatal PCB exposure, the corpus callosum, and response inhibition. Environmental Health Per- spectives 2003; 111: 1670.
  123. Stewart P, Reihman J, Gump B, Lonky E, Darvill T, Pagano J. Response inhibition at 8 and 9 1/2 years of age in children prenatally exposed to PCBs. Neurotoxicology and Teratology 2005; 27: 771-80.
  124. Neugebauer J, Wittsiepe J, Kasper-Sonnenberg M, Schöneck N, Schölmerich A, Wil- helm M. The influence of low level pre-and perinatal exposure to PCDD/Fs, PCBs, and lead on attention performance and attention-related behavior among German school-aged children: results from the Duisburg Birth Cohort Study. International Journal of Hygiene and Environmental Health 2015; 218: 153-62.
  125. Boucher O, Jacobson SW, Plusquellec P, Dewailly É, Ayotte P, Forget-Dubois N, et al. Prenatal methylmercury, postnatal lead exposure, and evidence of attention deficit/ hyperactivity disorder among Inuit children in Arctic Québec. Environmental Health Perspectives 2012; 120: 1456-61.
  126. Sagiv SK, Thurston SW, Bellinger DC, Amarasiriwardena C, Korrick SA. Prenatal ex- posure to mercury and fish consumption during pregnancy and attention-deficit/ hyperactivity disorder-related behavior in children. Archives of Pediatrics & Adoles- cent Medicine 2012; 166: 1123-31.
  127. Ha M, Kwon H-J, Lim M-H, Jee Y-K, Hong Y-C, Leem J-H, et al. Low blood levels of lead and mercury and symptoms of attention deficit hyperactivity in children: a re- port of the children's health and environment research (CHEER). Neurotoxicology 2009; 30: 31-6.
  128. Yoshimasu K, Kiyohara C, Takemura S, Nakai K. A meta-analysis of the evidence on the impact of prenatal and early infancy exposures to mercury on autism and atten- tion deficit/hyperactivity disorder in the childhood. Neurotoxicology 2014; 44: 121-31.
  129. Quirós-Alcalá L, Mehta S, Eskenazi B. Pyrethroid pesticide exposure and parental re- port of learning disability and attention deficit/hyperactivity disorder in US Chil- dren: NHANES 1999-2002. Environmental Health Perspectives 2014; 122: 1336.
  130. Mick E, Biederman J, Faraone SV. Is season of birth a risk factor for attention-deficit hyperactivity disorder? Journal of the American Academy of Child & Adolescent Psychiatry 1996; 35: 1470-6.
  131. Chotai J, Serretti A, Lattuada E, Lorenzi C, Lilli R. Gene-environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hy- droxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms. Psychiatry Research 2003; 119: 99-111.
  132. Liederman J, Flannery KA. Fall conception increases the risk of neurodevelopmental disorder in offspring. Journal of Clinical and Experimental Neuropsychology 1994; 16: 754-68.
  133. Tosini G, Dirden JC. Dopamine inhibits melatonin release in the mammalian retina: in vitro evidence. Neuroscience Letters 2000; 286: 119-22.
  134. Seeger G, Schloss P, Schmidt MH, Rüter-Jungfleisch A, Henn FA. Gene-environment interaction in hyperkinetic conduct disorder (HD+ CD) as indicated by season of birth variations in dopamine receptor (DRD4) gene polymorphism. Neuroscience Letters 2004; 366: 282-6.
  135. Brookes KJ, Neale B, Xu X, Thapar A, Gill M, Langley K, et al. Differential dopamine receptor D4 allele association with ADHD dependent of proband season of birth. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2008; 147: 94-9.
  136. Karakurt MN, Karabekiroğlu MK, Akbaş S, Bilgici B, Kılıç M, Şenses A, et al. Associ- ation between symptom profiles and iron and ferritine serum levels in children with attention deficit hyperactivity disorder research article. 2011; 48:125-128.
  137. Erikson KM, Jones BC, Hess EJ, Zhang Q, Beard JL. Iron deficiency decreases dopa- mine D1 and D2 receptors in rat brain. Pharmacology Biochemistry and Behavior 2001; 69(3): 409-18.
  138. Konofal E, Lecendreux M, Arnulf I, Mouren M-C. Iron deficiency in children with at- tention-deficit/hyperactivity disorder. Archives of Pediatrics & Adolescent Medicine 2004; 158: 1113-5.
  139. Oner O, Alkar OY, Oner P. Relation of ferritin levels with symptom ratings and cog- nitive performance in children with attention deficit-hyperactivity disorder. Pedia- trics International 2008; 50: 40-4.
  140. Konofal E, Lecendreux M, Deron J, Marchand M, Cortese S, Zaïm M, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pedia- tric Neurology 2008; 38: 20-6.
  141. Oner P, Oner O, Cop E, Munir KM. Effect of ferritin on short-term treatment re- sponse in attention deficit hyperactivity disorder. Bulletin of Clinical Psychopharma- cology 2012; 22: 325-31.
  142. Famularo R, Kinscherff R, Fenton T. Psychiatric diagnoses of maltreated children: preliminary findings. Journal of the American Academy of Child & Adolescent Psy- chiatry 1992; 31: 863-7.
  143. McLEER SV, Callaghan M, Henry D, Wallen J. Psychiatric disorders in sexually abused children. Journal of the American Academy of Child & Adolescent Psychiatry 1994; 33: 313-9.
  144. Gurevitz M, Geva R, Varon M, Leitner Y. Early markers in infants and toddlers for development of ADHD. Journal of Attention Disorders 2014; 18: 14-22.
  145. Latimer K, Wilson P, Kemp J, Thompson L, Sim F, Gillberg C, et al. Disruptive be- haviour disorders: a systematic review of environmental antenatal and early years risk factors. Child: Care, Health and Development 2012; 38: 611-28.
  146. Kendall J, Leo MC, Perrin N, Hatton D. Modeling ADHD child and family relation- ships. Western Journal of Nursing Research 2005; 27: 500-18.
  147. McLaughlin KA, Sheridan MA, Winter W, Fox NA, Zeanah CH, Nelson CA. Wide- spread reductions in cortical thickness following severe early-life deprivation: a neu- rodevelopmental pathway to attention-deficit/hyperactivity disorder. Biological Psychiatry 2014; 76: 629-38.
  148. Whalen CK, Henker B. The child with attention-deficit/hyperactivity disorder in fam- ily contexts. In: Handbook of disruptive behavior disorders. Springer; 1999, p. 139-55.
  149. Danforth JS. The outcome of parent training using the behavior management flow chart with mothers and their children with oppositional defiant disorder and atten- tion-deficit hyperactivity disorder. Behavior Modification 1998; 22(4): 443-73.
  150. Weiss G, Hechtman LT. Hyperactive children grown up: ADHD in children, adoles- cents, and adults. Guilford Press, New York;1993.
  151. González, J.J., et al., Performance analysis of univariate and multivariate EEG measure- ments in the diagnosis of ADHD. Clinical neurophysiology: official journal of the Inter- national Federation of Clinical Neurophysiology, 2013. 124: p. 1139-50.
  152. Friston, K.J., Functional and effective connectivity: a review. Brain Connect, 2011. 1(1): p. 13-36.
  153. van Diessen, E., et al., Opportunities and methodological challenges in EEG and MEG rest- ing state functional brain network research. Clin Neurophysiol, 2014. In press.
  154. Cohen, M.X., Comparison of different spatial transformations applied to EEG data: A case study of error processing. Int J Psychophysiol, 2015. In press.
  155. Rulkov, N.F., et al., Generalized synchronization of chaos in directionally coupled chaotic systems. Physical Review E, 1995. 51(2): p. 980-994.
  156. Chicharro, D. and R.G. Andrzejak, Reliable detection of directional couplings using rank statistics. Physical Review E, 2009. 80(2): p. 26217.
  157. Takens, F. Detecting strange attractors in turbulence. 1980. Springer.
  158. Sauer, T., J.A. Yorke and M. Casdagli, Embedology. Journal of Statistical Physics, 1991. 65: p. 579-616.
  159. Quiroga, R.Q., J. Arnhold and P. Grassberger, Learning driver-response relationships from synchronization patterns. Physical Review. E, 2000. 61(5 Pt A): p. 5142-5148.
  160. Quiroga, R.Q., et al., Performance of different synchronization measures in real data: A case study on electroencephalographic signals. Physical Review E, 2002. 65(4 Pt 1): p. 41903-41903.
  161. Andrzejak, R.G., et al., Bivariate surrogate techniques: Necessity, strengths, and caveats. Physical Review E, 2003. 68(6): p. 66202.
  162. Barry, R.J., et al., Age and gender effects in EEG coherence: III. Girls with attention-deficit/ hyperactivity disorder. Clin Neurophysiol, 2006. 117(2): p. 243-51. Assessment of ADHD Through Electroencephalographic Measures of Functional Connectivity http://dx.doi.org/10.5772/60559 · DOI
  163. Marsland, S., Machine Learning: An Algorithmic Perspective, Second Edition. 2nd ed. Chapman & Hall/CRC Machine Learning & Pattern Recognition. 2014: Chapman & Hall/CRC.
  164. Kugiumtzis, D., Direct-coupling information measure from nonuniform embedding. Physi- cal Review E, 2013. 87(6): p. 062918.
  165. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012;9(3):490-9.
  166. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence esti- mates across three decades: an updated systematic review and meta-regression anal- ysis. Int J Epidemiol 2014;43(2):434-42.
  167. Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: metaanalysis. Brit J Psychiatr 2009;194(3): 204-11.
  168. Ramos-Quiroga JA, Nasillo V, Fernández-Aranda F, Casas M. Addressing the lack of studies in attention-deficit/hyperactivity disorder in adults. Exp Rev Neurotherapeu- tics 2014;14(5):553-67.
  169. Thapar A, Cooper M, Eyre O, Langley K. What have we learnt about the causes of ADHD? J Child Psychol Psychiatr 2013;54(1):3-16.
  170. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatr 2005;57(11):1313-23.
  171. Li Z, Chang SH, Zhang LY, Gao L, Wang J. Molecular genetic studies of ADHD and its candidate genes: a review. Psychiatr Res 2014;219(1):10-24.
  172. Akutagava-Martins GC, Salatino-Oliveira A, Kieling CC, Rohde LA, Hutz MH. Ge- netics of attention-deficit/hyperactivity disorder: current findings and future direc- tions. Exp Rev Neurotherapeutics 2013;13(4):435-45.
  173. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a metaanalytic re- view. Human Genetics 2009;126(1):51-90.
  174. Scassellati C, Bonvicini C, Faraone SV, Gennarelli M. Biomarkers and attention-defi- cit/hyperactivity disorder: a systematic review and meta-analyses. J Am Acad Child Adolesc Psychiatr 2012;51(10):1003-19.
  175. Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit hyperactivity disorder. Attention Deficit Hyperactivity Disorders 2010;2(4):241-55.
  176. Findling RL. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Therapeut 2008;30(5):942-57.
  177. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacother- apy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adoles Psychiatr 1996;35(4):409-32.
  178. Swanson J, Baler RD, Volkow ND. Understanding the effects of stimulant medica- tions on cognition in individuals with attention-deficit hyperactivity disorder: a dec- ade of progress. Neuropsychopharmacology 2011;36(1):207-26.
  179. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adoles Psychiatr 2010;19(4):353-64.
  180. Faraone SV. Using meta-analysis to compare the efficacy of medications for atten- tion-deficit/hyperactivity disorder in youths. P & T: J Formul Manage 2009;34(12): 678-94.
  181. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention- deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-re- gression analysis. Psychopharmacology (Berl) 2007;194(2):197-209.
  182. Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct compari- son meta-analysis. J Attent Disorders 2011;15(8):674-83.
  183. Dvoráková M, Jezová D, Blazícek P, Trebatická J, Skodácek I, Suba J, Duracková Z. Urinary catecholamines in children with attention deficit hyperactivity disorder (ADHD): modulation by a polyphenolic extract from pine bark (pycnogenol). Nutrit Neurosci 2007;10(3-4):151-7.
  184. De Sousa A, Kalra G. Drug therapy of attention deficit hyperactivity disorder: cur- rent trends. Mens sana Monographs 2012;10(1):45-69.
  185. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: pre- ferred definitions and conceptual framework. Clin Pharmacol Therapeut 2001;69(3): 89-95.
  186. Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagno- sis, treatment, and pathophysiology. Neuropsychopharmacol 2011;36(12):2375-94.
  187. Singh I, Rose N. Biomarkers in psychiatry. Nature 2009;460(7252):202-7. Role of Dopaminergic and Noradrenergic Systems as Potential Biomarkers in ADHD Diagnosis and Treatment http://dx.doi.org/10.5772/60860 tions and confirms candidate gene associations. Am J Med Genet B, Neuropsychiatr Genet 2008;147B(8):1345-54. · doi:10.5772/60860tionsandconfirmscandidategeneassociations
  188. Sun HJ, Yuan FF, Shen XM, Xiong GL, Wu J. Role of COMT in ADHD: a systematic meta-analysis. Molecular Neurobiol 2014;49(1):251-61.
  189. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. Brit Med J 1997;315(7121):1533-7.
  190. Shaywitz BA, Sullivan CM, Anderson GM, Gillespie SM, Sullivan B, Shaywitz SE. Aspartame, behavior, and cognitive function in children with attention deficit disor- der. Pediatrics 1994;93(1):70-5.
  191. Zametkin AJ, Linnoila M, Karoum F, Sallee R. Pemoline and urinary excretion of cat- echolamines and indoleamines in children with attention deficit disorder. Am J Psy- chiatr 1986;143(3):359-62.
  192. Zametkin AJ, Karoum F, Linnoila M, Rapoport JL, Brown GL, Chuang LW, Wyatt RJ. Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A compari- son of methylphenidate and dextroamphetamine. Arch Gen Psychiatr 1985;42(3):251- 55a.
  193. Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Karoum F, Potter WZ, Ismond D. Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. Arch Gen Psychiatr 1985;42(10): 969-73 b.
  194. Rapoport JL, Mikkelsen EJ, Ebert MH, Brown GL, Weise VK, Kopin IJ. Urinary cate- cholamines and amphetamine excretion in hyperactive and normal boys. J Nervous Mental Disease 1978;166(10):731-7.
  195. Elia J, Borcherding BG, Potter WZ, Mefford IN, Rapoport JL, Keysor CS. Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Therapeut 1990;48(1):57-66.
  196. Zametkin AJ, Hamburger SD. The effect of methylphenidate on urinary catechola- mine excretion in hyperactivity: a partial replication. Biol Psychiatr 1988;23(4):350-6.
  197. Shekim WO, Javaid J, Davis JM, Bylund DB. Urinary MHPG and HVA excretion in boys with attention deficit disorder and hyperactivity treated with d-amphetamine. Biol Psychiatr 1983;18(6):707-14.
  198. Brown GL, Ebert MH, Hunt RD, Rapoport JL. Urinary 3-methyoxy-4-hydroxyphe- nylglycol and homovanillic acid response to d-amphetamine in hyperactive children. Biol Psychiatr 1981;16(8):779-87.
  199. Shekim WO, Dekirmenjian H, Chapel JL, Javaid J, Davis JM. Norepinephrine metab- olism and clinical response to dextroamphetamine in hyperactive boys. J Pediatr 1979;95(3):389-94a. Role of Dopaminergic and Noradrenergic Systems as Potential Biomarkers in ADHD Diagnosis and Treatment http://dx.doi.org/10.5772/60860 · DOI
  200. Shen YC, Wang YF. Urinary 3-methoxy-4-hydroxyphenylglycol sulfate excretion in seventy-three schoolchildren with minimal brain dysfunction syndrome. Biol Psy- chiatr 1984;19(6):861-70.

200 of 952 shown

Cited by

See all 23

Metadata

Authors
Norvilitis, J. M.
Corresponding author
Jill M. Norvilitis
Venue
InTech eBooks
Publisher
InTech
Published
2015-09-24
OpenAlex
W2505058009
Cited by
23
References
0
Citations by year
2025: 2 · 2024: 8 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 1 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 1
FWCI
2.24
Type
book
Language
en
Open access
Licence
cc-by
Locations
InTech eBooks (publishedVersion)
Funders
  • Ministerio de Economía y Competitividad
  • Korea Health Industry Development Institute
  • Ministry of Education, India
  • National Center of Neurology and Psychiatry
  • Japan Society for the Promotion of Science (15H05405, 15K13167)
  • Instituto de Salud Carlos III
  • European Regional Development Fund
  • Office of Naval Research
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
Keywords
attention deficit hyperactivity disorder, ADHD diagnosis, ADHD treatment, ADHD etiology, comorbidities, biomarkers, executive function, cognitive function, social functioning, complementary and alternative medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ADHD - New Directions in Diagnosis and Treatment. https://app.cochat.ai/papers/10.5772/59348
The paper
Norvilitis, J. M. (2015). ADHD - New Directions in Diagnosis and Treatment. InTech eBooks. https://doi.org/10.5772/59348

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.